3 Game-Changing Small-Cap Healthcare Stocks

The ability to shake up patient treatment could mean big bucks for Tetraphase Pharmaceuticals (NASDAQ: TTPH), NovoCure (NASDAQ: NVCR), and Exact Sciences (NASDAQ: EXAS). Should you be buying shares in these companies? Read on to learn if they're right for your portfolio.

What happens when a highly anticipated phase 3 study fails to pan out? Shares get crushed. And that's precisely what happened when Tetraphase Pharmaceuticals reported in 2015 that its oral antibiotic, eravacycline, missed the mark as a treatment for urinary tract infection.

IMAGE SOURCE: GETTY IMAGES.

Continue reading


Source: Fool.com